Arthritis Drug Curbs Excessive Drinking in Early Study

People researching medical detox and treatment for heavy drinking have a new line of science to watch, even if it is not yet a treatment they can ask for.

A study from Scripps Research found that an FDA-approved anti-inflammatory drug, the kind used for rheumatoid arthritis, reduced excessive drinking in alcohol-dependent female mice by calming inflammation in the brain.

The findings were published in the Journal of Neuroinflammation on May 22, 2026, and reported by Neuroscience News. They add to a growing body of evidence that brain inflammation plays a role in alcohol use disorder (AUD).

Why Medical Detox Still Comes First

Before getting to the science, one point matters most for safety. This research is early and does not change how alcohol dependence is treated today.

Alcohol withdrawal can be life-threatening, with risks that include seizures and delirium tremens, so anyone who drinks heavily and wants to stop should never attempt to detox alone at home. Medical detox provides monitoring and medications that make withdrawal safer.

What the Researchers Found

The study centered on interleukin-6, or IL-6, a molecule the body produces in response to stress, infection and injury. IL-6 is well known for driving inflammation in diseases like rheumatoid arthritis, but brain cells produce it too. Earlier work had linked heavy drinking to elevated IL-6 and tied a variant in the IL-6 gene to higher AUD risk.

Senior author Marisa Roberto and colleagues confirmed that chronic alcohol exposure raised IL-6 signaling in the central amygdala, a brain region tied to addiction.

There, IL-6 suppressed the brain’s GABA system, which normally acts as a brake on overactive neurons. When that brake weakens, the result can include cravings, compulsive drinking, and withdrawal symptoms.

When the team gave alcohol-dependent mice an antibody that blocks the IL-6 receptor, the same class of drug used for arthritis, dependent female mice drank significantly less.

Dependent males and non-dependent animals showed no significant change. The team also analyzed postmortem brain tissue from 30 people with AUD and 30 without, identifying 377 genes expressed differently between the groups, with IL-6 among the strongest elevated signals.

Understanding the Sex Difference

The drug worked in females but not males, which the researchers connected to the fact that women are more prone to autoimmune and inflammatory conditions.

They cautioned that more work is needed, noting the female mice also drank more to begin with, which could partly explain the difference. In other words, this is a promising target, not a finished therapy.

How This Connects to Treatment

Today, medication-assisted treatment for AUD relies on approved options such as naltrexone, acamprosate, and disulfiram, used alongside counseling and, when needed, medical detox.

An IL-6 based approach is not among them yet and has not been tested as an AUD treatment in humans. What the study offers is a possible future direction and a reframing of AUD as a whole-body, treatable medical condition rather than a personal failing.

Finding Medical Detox

If heavy drinking is part of your life, the safest first step is medically supervised care, not an experimental or at-home approach. Never attempt alcohol detox without medical supervision.

You can search detox.com’s directory to find medical detox centers near you. Call 800-996-6135(Sponsored) to speak with a treatment advisor. You can ask about medication-assisted treatment options, and confirm what level of monitoring a program provides for alcohol withdrawal.